Ampligen

佛罗里达州奥卡拉, June 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)（以下简称“AIM”或“公司”）今日宣布发表临床前数据，数据表明 Ampligen 有可能直接作用于肿瘤细胞，抑制肿瘤细胞在肿瘤 TLR-3 水平足够的胰腺癌患者中的生长，这意味着有种潜在的生物标志物可识别出可能对 Ampligen 产生反应的患者。该抗肿瘤分析发表在同行评议期刊《美国癌症研究杂志》题为…

OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel…

OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune…

OCALA, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune…

Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer OCALA,…

OCALA, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune…

OCALA, Fla., June 14, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” of het “Bedrijf”), een immunofarmaceutisch bedrijf dat zich toelegt op het onderzoek naar en de ontwikkeling van therapeutica voor de…

OCALA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune…

OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers,…

OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI)…